Clinical Trials
43 trialsComparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
Oslo University Hospital
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Memorial Sloan Kettering Cancer Center
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
TVNIM-AFU
Association Francaise d'Urologie
CISTO2
University of Washington
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
ADAPT-BLADDER
Hoosier Cancer Research Network
ENHANCE
Hoosier Cancer Research Network
GAIN-BCG
Alliance for Clinical Trials in Oncology
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
MiLUT
University of Zurich
PRO-GAG
BLAD-HYA Group
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Ohio State University Comprehensive Cancer Center
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Hydeal Cyst
Istituto Oncologico Veneto IRCCS
SPICE
University of Aarhus
CUT-less
University of Roma La Sapienza
BicaBCa
CHU de Quebec-Universite Laval
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Johns Hopkins University
COBRA-NMIBC
Aarhus University Hospital
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Lahey Clinic
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
Ractigen Therapeutics.
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
University of Texas Southwestern Medical Center
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
The First Affiliated Hospital with Nanjing Medical University
COBRA
Medical University of Vienna
Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer
Yunnan Cancer Hospital
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
Peking University First Hospital
eRapa
The University of Texas Health Science Center at San Antonio
HIGCrecur
Changhai Hospital
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
Tongji Hospital
PRIMER
University of Virginia
DURANCE
University College, London
A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer
The Affiliated Hospital of Xuzhou Medical University
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
ProCaB
Universitaire Ziekenhuizen KU Leuven
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
The First Affiliated Hospital with Nanjing Medical University
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
IRCCS San Raffaele
TROJAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
OPTIMA
Aarhus University Hospital